In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .
B Vitamin and/or n-3 Fatty Acid Supplementation and Health-Related Quality of Life: Ancillary Findings from the SU.FOL.OM3 Randomized Trial
Background Despite growing attention to nutrition and quality of life in cardiovascular disease survivors , the impact of dietary factors according to disease type or to quality of life domain is poorly understood . We investigated the effects of B vitamin and /or n-3 fatty acid supplementation on health-related quality of life among survivors of stroke , myocardial infa rct ion , or unstable angina . Methods We performed ancillary analyses of the SU.FOL.OM3 trial ( 2003–2009 ; France ) . In total , 2,501 men ( mean age = 61 y ) and women ( mean age = 63 y ) were r and omized in a 2 × 2 factorial design to : 1 ) 0.56 mg 5-methyl-tetrahydrofolate , 3 mg vitamin B6 , 0.02 mg vitamin B12 ; 2 ) 600 mg eicosapentaenoic and docosahexaenoic acids in a 2∶1 ratio ; 3 ) B vitamins and n-3 fatty acids combined ; or 4 ) placebo . Health-related quality of life was evaluated at follow-up with the Medical Outcomes Study 36-Item Short Form Health Survey . Data from 2,029 individuals were used in this analysis . Results After 3.1±0.4 y , no effects of supplementation with either B vitamins  or n-3 fatty acids on quality of life ( physical or mental health domains ) were found . However , participants receiving B vitamins had slightly more activity limitations due to emotional problems compared with those not receiving B vitamins ( mean difference = 3.8 ; 95 % CI : 0.4 , 7.1 ) . A significant interaction of treatment by prior disease revealed an inverse association between n-3 fatty acids and vitality among myocardial infa rct ion survivors ( mean difference = 2.9 ; 95 % CI : 0.5 , 5.2 ) . Conclusions There were no beneficial effects of supplementation with relatively low doses of B vitamins or n-3 fatty acids on health-related quality of life in cardiovascular disease survivors . The adverse effects of B vitamins on activity limitations and of n-3 fatty acids on vitality among individuals with prior myocardial infa rct ion merit confirmation
In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .